Zug, Zug, Switzerland
Senior healthcare executive and trained Swiss physician with extensive experience building, scaling, and leading high-value innovative medical technology companies. Proven track record in venture capital-backed, early-stage startups, and global public corporations across the US and Europe. Expert in sales and marketing leadership (go-to-market strategies and business turnarounds), clinical research, Chief Medical Officer (CMO) duties, fundraising ($36M Series B), and corporate exit execution (NASDAQ IPOs, M&A). Fluent in multiple languages with deep global commercialization expertise. Core skills and defining experience: Global business building in the US, all EU and selected APac / LatAm markets. Track record in value proposition building, market access, KOL engagement, commercial strategy from start-ups to corporate post-M&A. Medical strategic and operational expertise: Clinical and medical strategy building, advisory panel strategy and lead, product (re-)positioning, shaping and driving commercial adoption ‘HCP pull’ framework. Inspiring front-line leadership style: Agile, fast pattern-recognizer – highly perceptive of unmet opportunities. Building of high-performance teams focused on the ‘joy of doing and winning together’. Patient-centric value creator: ‘Doing the right things’ and ‘Doing things right’ with no short-cuts, highest ethical standards and uncompromised quality.
• Re-ignited strong sequential and YoY topline growth with refined surgical technique re-launch. Restructured commercial team, focused strategy on core markets and tripled revenue per commercial FTE. • Increased addressable market through evidence-based re-positioning of MINIject in continuum of care through increased medical affairs team focus and bandwidth. • Global KOL relationship management in commercial and clinical research context.
• Led US PME trial through completion of initial phase, 2023 FDA approval for full enrollment, and subsequent tripling of participating sites in the US, Canda and Europe. • Quadrupled US enrollment speed through creation of field based clinical operations team with focus on site training and engagement. Obtained favorable protocol amendment following FDA pre-sub meeting with strong KOL support. • Restructured clinical research team for increased focus, and relaunched enrollment of 249 subjects into real-life registry in Europe. Secured 5-year follow up on global regulatory trials.
• Launched MINIject into selected, rapid-access markets/accounts with focus on long-term, high-quality KOL collaboration with leading glaucoma surgeons. • Built global KOL network and advisory panel with continuous pre- to post-launch input into commercial rollout. Created training / market access / pricing / commercial go-to-market strategy, and built focused commercial team post-approval.
Stocker Healthcare Consulting offers early-stage medical technology companies a one-stop-shopping strategic and operational toolbox to develop their technology into a product, or a product into a diagnostic or therapeutic solution ready for commercial launch. We support you in the design implementation of your clinical research towards value-generating study results with quality, in time and in budget. We create buy-in by regulatory bodies, healthcare professionals, patients and payers prior to launch and beyond. And we help you execute your commercial with ambitious goals for fast market adoption. We create your WIN-WIN-WIN.
• 1997-1998: Intern at Zurich University Hospital • Clinical practice and research in clinical pharmacology and personalized medicine; 8 publications • 1996-today: I am serving as a physician in the Swiss Army (www.armee.ch)
• Medical and clinical leadership: FDA presubmission, first-in-man trial design, presentations at ATTD and EASD • Market access strategy development for US and EU • Commercial product positioning and value message towards key stake holders • Instrumental in rising €38M Series B funding
• CGM market know-how input for product design 2017-2019 • Created diabetes technology key stake holder awareness of INDIGO in US and Europe • Built and pitched medical and commercial value proposition for Series B round 2019/2020
• Commercial lead for 63% of global revenue P&L in 9 major countries • Turned around biggest market (DACH) back to double-digit growth • Increased margins and topline growth with go-direct in Spain, Italy and France